On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
District Court
-
-
On February 21, 2019, Sandoz Inc. (“Sandoz”) filed suit against Amgen Inc. and Amgen Manufacturing Limited (collectively “Amgen”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We previously wrote about Genentech’s U.S. Patent No. 6,407,213 (“the ’213 patent”) to Carter, first in October 2017, and more...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In a 104-page ruling, U.S. District Judge Mark L. Wolf granted summary judgment in favor of Celltrion and Hospira, finding that a doctrine...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a number of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. recently scored a victory in their ongoing dispute over a...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On December 20, 2017, Bristol Myers Squibb Company, Bavarian Nordic, and Enzo Biochem, Inc. filed an amicus brief in support of Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In October, a Federal Circuit panel vacated a permanent injunction against Sanofi and Regeneron’s Praluent® and remanded the proceeding...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]